La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

PuraPharm Dividende

Dividende contrôle des critères 0/6

PuraPharm ne verse actuellement pas de dividende.

Informations clés

Rendement du dividende

Ratio de distribution

Rendement moyen de l'industrie	3.8%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	HK$0.0202
Résultat par action	-HK$0.27
Prévisions de rendement du dividende à 3 ans	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

Feb 06

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de 1498 ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de 1498 ont augmenté.

Rendement des dividendes par rapport au marché

PuraPharm Rendement des dividendes par rapport au marché

Comment le rendement du dividende de 1498 se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (1498)	0%
25% du marché (HK)	3.5%
25% du marché (HK)	8.4%
Moyenne du secteur (Pharmaceuticals)	3.8%
Prévisions des analystes dans 3 ans (1498)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de 1498 par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de 1498 par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: 1498 ne verse pas de dividende notable pour le marché Hong Kong.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car 1498 n'a signalé aucun versement.

PuraPharm Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

PuraPharm Corporation Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2024

PuraPharm Corporation Limited to Report First Half, 2024 Results on Aug 28, 2024

PuraPharm Corporation Limited has withdrawn its Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited has filed a Follow-on Equity Offering in the amount of HKD 39 million.

PuraPharm Corporation Limited, Annual General Meeting, May 24, 2024

PuraPharm Corporation Limited to Report Fiscal Year 2023 Results on Mar 25, 2024

Risks To Shareholder Returns Are Elevated At These Prices For PuraPharm Corporation Limited (HKG:1498)

PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2023 earnings released: HK$0.095 loss per share (vs HK$0.10 loss in 1H 2022)

PuraPharm Corporation Limited to Report First Half, 2023 Results on Aug 29, 2023

Less than half of directors are independent

PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director

Full year 2022 earnings released: HK$0.30 loss per share (vs HK$0.31 loss in FY 2021)

PuraPharm (HKG:1498) Has Debt But No Earnings; Should You Worry?

First half 2022 earnings released: HK$0.10 loss per share (vs HK$0.03 profit in 1H 2021)

PuraPharm Corporation Limited to Report First Half, 2022 Results on Aug 27, 2022

Purapharm Corporation Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022

Founder recently bought HK$118k worth of stock

Less than half of directors are independent

Purapharm Corporation Limited Announces Retirement of Non-Executive Director

Full year 2021 earnings released: HK$0.31 loss per share (vs HK$0.086 profit in FY 2020)

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited, Annual General Meeting, May 23, 2022

PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021

Investor sentiment improved over the past week

Founder recently bought HK$86k worth of stock

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

Is PuraPharm (HKG:1498) A Risky Investment?

First half 2021 earnings released: EPS HK$0.03 (vs HK$0.033 in 1H 2020)

CFO & Company Secretary Ka Kuen Lau has left the company

Independent Non-Executive Director Kin Keung Chan has left the company

Executive Vice-Chairman Kam Biu Tsoi has left the company

Non-Executive Director Kin Man Chan has left the company

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm's (HKG:1498) Profits Appear To Have Quality Issues

Full year 2020 earnings released: EPS HK$0.086 (vs HK$0.87 loss in FY 2019)

PuraPharm Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day high: HK$0.80

New 90-day high: HK$0.78

Founder recently bought HK$54k worth of stock

New 90-day low: HK$0.66

How Much Is PuraPharm Corporation Limited (HKG:1498) Paying Its CEO?

PuraPharm Corporation Limited Appoints Norimoto Hisayoshi as Executive Director, Effect from 17 November 2020

First half earnings released

Founder recently sold HK$9.5m worth of stock

New 90-day high - HK$0.80

Earnings released

PuraPharm Corporation Limited to Report First Half, 2020 Results on Aug 25, 2020

New 90-day low - HK$0.60

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés